The new company will separate the fast-growing eye business from Bausch Health’s pharmaceutical business, the report said. The initial public offering values the company at $8.4 billion.
The spinoff has been planned since at least 2020, the report said.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
